Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
MDS updates from iwMDS-iwMPN 2024
2nd International Workshop on MDS & MPNs
28–30 June 2024 | Boston, MA
Expert-led presentations & roundtable discussions on myelodysplastic syndromes from iwMDS/iwMPN 2024.
iwMDS/iwMPN 2024 was supported by BMS, AbbVie, Astex Pharmaceuticals, Geron, Keros Therpaeutics, Sobi, Menarini-Stemline, Syros, Agios and GSK. Supporters have no influence over the production of the content.
Rising STARs session
New directions & governmental efforts
European MDS trials
Inflammation & immune interventions
Classification & risk stratification updates
Keynote talk
Response assessment & regulatory considerations
TP53 aberrations & secondary AML
Updates in HR-MDS therapies
Advances in LR-MDS therapies
Big data & quality of life measures
Rising STARs session: MDS in special populations Part 1
DDX41-mut MDS/AML
Carmelo Gurnari Cleveland Clinic, Cleveland, OH, United States
MDS in young patients
Yasmin Abaza Northwestern University, Chicago, IL, United States
Cohesin genes mutated MDS - a distinct entity?
Tariq Kewan Yale School of Medicine, New Haven, CT, United States
How to approach hypoplastic MDS
Emma Groarke The National Heart, Lung, and Blood Institute, DC, WA, United States
Targeting splicing mutation-mutated MDS
Jan Bewersdorf Yale Cancer Center, New Haven, CT, United States
How should TP53-mutated MDS be classified?
Bing Li Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
New digital tools in hematology
Anne Sophie Kubasch University of Leipzig, Leipzig, Germany
New directions and governmental efforts
Oral hypomethylating agents in MDS – what is next?
Elizabeth Griffiths Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States
Impact of responses to HMAs in context of baseline geneHc risk and transplant
Maximilian Stahl Yale Cancer Center, New Haven, CT, United States
Overview of the NIH program for MDS
Alain Mina National Cancer Institute, DC, WA, United States
Overview of CTEP/NCI efforts for MDS
Olatoyosi Odenike Duchossois Center for Advanced Medicine, Chicago, IL, United States
Improving governmental-academic collaborations
Steven Gore National Cancer Institute, Bethesda, MD, United States
Updates on European MDS trials
IST in MDS - the GFM experience
Marie Sebert Saint-Louis Hospital, Paris, France
Clinical trials of the D-MDS & EMSCO platforms
Uwe Platzbecker University Hospital Carl Gustav Carus, Dresden, Germany
FISiM clinical trials
Valeria Santini University of Florence, Florence, Italy
Inflammation and immune interventions
IRAK inhibitors in MDS and AML
Uwe Platzbecker University Hospital Carl Gustav Carus, Dresden, Germany
STAT3-targeting in MDS
Aditi Shastri Albert Einstein College of Medicine, New York City, NY, United States
Immune checkpoint use in MDS/AML – a dead end?
Amer Zeidan Yale University School of Medicine and Yale Cancer Center, New Haven, CT, United States
Classification and risk stratification updates
Roadmap for harmonization of classifications in MDS
Somedeb Ball Vanderbilt University Medical Center, Nashville, TN, United States
Classification boundaries between MDS and AML
Maria Teresa Voso Rome Tor Vergata University, Rome, Italy
Predicting relapse risk in MDS post-transplant
Christopher Hourigan Virginia Tech FBRI Cancer Research Center, Washington D.C, United States
Standardization of the path reporting in MDS – the icMDS recommendations
Robert Hasserjian Massachusetts General Hospital, Boston, MA, United States
Uniform & inclusive patient eligibility criteria for MDS CTs
Uma Borate Ohio State University, Columbus, OH, United States
Keynote talk
Proceedings from FDA/NCI workshop on drug development in MDS
Nina Kim U.S. Food & Drug Administration, Silver Spring, MD, United States
Response assessment & regulatory considerations
How can we measure disease modification in LR-MDS?
Rami Komrokji Moffitt Cancer Center, Tampa, FL, United States
How should MDS-IB2 (AML/MDS) be approached in clinic and trials?
Katharina Götze Technical University of Munich, Munich, Germany
Do we still need to do BM evaluations in MDS?
Lisa Pleyer Paracelsus Medical University, Salzberg, Austria
MRD negative CR as an endpoint in MDS
Arjan van de Loosdrecht Amsterdam UMC, Amsterdam, Netherlands
Standardized reporting of MDS clinical trials
Andrew Brunner Massachusetts General Hospital, Boston, MA, United States
TP53 aberrations and secondary AML
How to use TP53 status for clinical decisions in MDS
Coleman Lindsley Dana-Farber Cancer Institute, Boston, MA, United States
Therapies for secondary AML
Thomas Cluzeau Central University Hospital of Nice, France
Targeting the CD47-SIRPa axis in MDS/AML
David Sallman H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
Current and future perspectives in TP53-mutated AML
Andrew Wei Alfred Hospital and Monash University, Melbourne, Australia
Updates in HR-MDS therapies
How should we use IDH inhibitors in MDS?
Marie Sebert Saint-Louis Hospital, Paris, France
Updates in use of RARA agonists in MDS
Amy DeZern Thomas Jefferson University, Baltimore, MD, United States
Venetoclax in HR-MDS – SOC or not?
Yazan Madanat UT Southwestern Medical Center, Dallas, TX, United States
Transplantation in HR-MDS: who and how?
Gail Roboz Weill Medical College of Cornell University, New York City, NY, United States
New directions in management of HR-MDS
Andrew Wei Alfred Hospital and Monash University, Melbourne, Australia
Advances in LR-MDS therapies
Telomerase inhibition
Uwe Platzbecker University Hospital Carl Gustav Carus, Dresden, Germany
TGF pathway modulation
Amer Zeidan Yale University School of Medicine and Yale Cancer Center, New Haven, CT, United States
Is HIF targeting in MDS still a viable approach?
Valeria Santini University of Florence, Florence, Italy
How do I manage LR-MDS and open questions in 2024
Hetty Carraway Cleveland Clinic, Cleveland, OH, United States
Big data and quality of life measures
Evolving role of artificial intelligence for MDS
Adrián Mosquera Orgueira University Hospital of Santiago de Compostela, Santiago de Compostela, Spain
Clinical characteristics of MDS using registration data in Japan
Yasushi Miyazaki Atomic Bomb Disease Institute, Nagasaki, Japan
QoL assessment in MDS in trials and clinical practice
Fabio Efficace Italian Group for Adult Hematologic Diseases (GIMEMA), Rome, IL, Italy
Using RWD and QoL as meaningful endpoints in trials
Mikkael Sekeres Sylvester Comprehensive Cancer Center, Miami, FL, United States
Explore roundtable discussions
View all
Supported by:
